NEW YORK (GenomeWeb News) – Trilink BioTechnologies said today that it has inked a new licensing agreement with Biofortuna allowing the UK firm to use Trilink's hot start deoxynucleotides for freeze-drying molecular diagnostic kit development and production service.

Biofortuna offers this product to "diagnostic companies looking to develop stabilized molecular diagnostic kits," said Mike Bunce, chief science officer of Biofortuna, in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.

Because of an autoimmune disorder, a man has been shedding live polioviruses for 28 years, according to an analysis appearing in PLOS Pathogens.

Being in a long-term collaboration can increase researchers' citation rates by 17 percent, a recent analysis says.

By analyzing tweets, Canadian researchers examine the public's view of gene patenting.